Novel N,N-spiro acetal derivatives demonstrate potent in vitro Factor Xa inhibitory activity, suggesting potential as oral anticoagulants.
Should not yet change anticoagulant practice; leaves open whether these derivatives advance beyond in vitro FXa inhibition.
We have already reported unique compounds containing a N,O-spiro acetal structure as an orally active factor Xa (FXa) inhibitor. This time, we described a N,N-spiro acetal structure as an analogue of the N,O-spiro acetal structure for an orally active FXa inhibitor. The synthesis of these analogues could be achieved in a similar fashion to the N,O-spiro acetal synthesis. Consequently, FXa inhibitory activity was increased and more active compounds could be found (M58163: IC50=0.61 nM, M58169: IC50=0.58 nM). Additionally, the absolute configuration could be determined by X-ray crystallography analysis (M58169: (R)-config.).
No takes yet. Share an insight, caveat, or question.
Saitoh et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: